Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment ...

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

Johnson & Johnson (NYSE:JNJ) on Friday announced favorable data from a Phase 3 trial for icotrokinra (JNJ-2113), its ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at ...